Danvatirsen Plus Venetoclax

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

What's the purpose of the trial?

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

Trial status

Accepting patients

Phase

Phase 1

Enrollment

Last Updated

2 months ago

Am I Eligible

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Danvatirsen is a STAT3 targeting antisense oligonucleotide inhibitor that is being studied for use in several different kinds of cancer.
Venetoclax is a BCL-2 inhibitor that may work by blocking the action of the BCL-2 protein on some cancer cells which can lead to cell death.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Danvatirsen Monotherapy

Accepting patients

Danvatirsen + Venetoclax Combination Therapy

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.